MHRA approves lurbinectedin for adults with extensive-stage small cell lung cancer
On 23 September 2026, the Medicines and Healthcare products Regulatory Agency approved lurbinectedin, sold as Zepzelca, for adults with extensive-stage small cell lung cancer. The approval covers its use with atezolizumab as maintenance treatment for people whose cancer has not got worse after first-line induction therapy with atezolizumab, carboplatin and etoposide. That is a long clinical sentence, so it helps to slow it down. This is not a new medicine for every person with lung cancer. It is for a specific group: adults with a fast-moving form of lung cancer, at an advanced stage, who have already had an initial course of treatment and now need the next step to try to keep the disease under control.
Small cell lung cancer is one of the more aggressive forms of lung cancer. When doctors say "extensive-stage", they mean the cancer has spread far enough that it is being treated as a disease affecting more than one area, rather than something localised. The phrase "maintenance treatment" can also sound more complicated than it needs to. In simple terms, it means treatment given after the first round has done its job, with the aim of holding that response for longer. That is where lurbinectedin now fits in this approval.
According to the MHRA, lurbinectedin works by attaching to DNA inside cancer cells. You can think of DNA as the instruction set that tells cells how to grow and divide. When the drug damages that DNA, it disrupts the cancer cells' ability to multiply, which can lead to cancer cell death. The regulator also says the medicine reduces the activity of certain immune cells that help tumours grow. That matters because cancer is not only about the tumour itself. It is also about the conditions around it, and whether those conditions allow the disease to keep spreading.
For patients, the treatment routine matters just as much as the science. Lurbinectedin is not a tablet taken at home. It is given as an intravenous infusion over one hour, with the recommended dose given once every 21 days, and treatment should be started and supervised in a hospital or clinic by a healthcare professional. What this means in practice is regular appointments, monitoring and repeated checks on how well the treatment is working. Approval is only one part of the story. The other part is the day-to-day reality of living around appointments, tests and side effects.
The MHRA says its decision was based on a main study involving 483 adults with extensive-stage small cell lung cancer. In that study, patients receiving lurbinectedin with atezolizumab as maintenance treatment lived for an average of 13.2 months, compared with 10.6 months for patients receiving atezolizumab alone. The study also found that patients on the combination lived for an average of 5.4 months without their disease getting worse, compared with 2.1 months for those on atezolizumab alone. Those figures do not mean the medicine will work in exactly the same way for every person, but they do help explain why the regulator judged it to be a meaningful new option.
No cancer treatment comes without risks, and the MHRA is clear about that. The most common side effects reported with lurbinectedin include nausea, fatigue, anaemia, thrombocytopenia and neutropenia. In plain English, that can mean feeling sick, feeling very tired, and changes in blood cells that may affect energy levels, bruising or infection risk. Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the approval gives adults another treatment option and that safety will continue to be monitored through the Yellow Card scheme. If you are reading this as a patient or a relative, the practical advice is simple: speak to your doctor, pharmacist or nurse if side effects appear or worsen, and report suspected side effects through Yellow Card.
There is also a wider lesson here about how medicines regulation works in the UK. The new marketing authorisation was granted on 23 September 2026 to Pharma Mar, S.A., and the MHRA says fuller prescribing information and patient leaflets will be published on its products website within seven days of approval. This medicine was submitted through the International Recognition Procedure, Route B, with the European Medicines Agency acting as the reference regulator. Put simply, that means the MHRA can use assessment work already carried out by another trusted regulator while still making its own UK decision about whether the benefits justify the risks. For readers trying to make sense of the headline, the key point is this: approval means one more licensed option now exists for a very specific group of adults with extensive-stage small cell lung cancer. It is a regulatory decision, a clinical decision and, for some families, a deeply personal piece of news all at once.